Hint mode is switched on Switch off
For swift navigation between sections

Annexin Pharmaceuticals
LEI 5493000JP703HGPJEX27

PDF download

Choose all Reset all
Download Cancel
Organization name
Annexin Pharmaceuticals AB
Country name
Sweden
Country of registration
Sweden
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.

Awards

News

21/07/2026 Citigroup Initiates 'Underperform' Rating on Annexon (NASDAQ: ANNX)
All organization news

Documentation

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    5493000JP703HGPJEX27
  • NACE
    *** ***
  • NAICS
    *** ***
  • Organisationsnummer
    556960-9539
Registration is required to get access.